EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects-Reference-Cited by-同舟云学术

EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects

Published:2023-07 Issue:4 Volume:98 Page:429-439
ISSN:0365-0596
Container-title:Anais Brasileiros de Dermatologia
language:en
Short-container-title:Anais Brasileiros de Dermatologia

Author:

Recuero Júlia Kanaan^ORCID,Fitz Joana Roberta^ORCID,Pereira Andrea Abe^ORCID,Bonamigo Renan Rangel^ORCID

Publisher

Elsevier BV

Subject

Dermatology

Reference52 articles.

1. Epidemiology and risk factors for drug allergy;Thong;Br J Clin Pharmacol,2011

2. Reações cutâneas a drogas em pacientes internados: relato de uma série de casos identificados pela farmacovigilância;Ghirlinzoni;Rev Bras Alerg Imunolpatol,2012

3. Skin problems and EGFR-tyrosine kinase inhibitor;Kozuki;Jpn J Clin Oncol,2016

4. The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors;Owczarek;Postepy Dermatol Alergol,2017

5. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients with Metastatic Colorectal Cancer: A Systematic Review;Lacouture;Clin Colorectal Cancer,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging targeted therapies in oral oncology: Focus on EGFR inhibition;Oral Oncology Reports;2024-09

2. Manifestaciones cutáneas asociadas al uso de cetuximab;Piel;2024-05

3. 5-Fluorouracil and Anti-EGFR antibody scaffold chitosan-stabilized Pickering emulsion: Formulations, physical characterization, in-vitro studies in NCL-H226 cells, and in-vivo investigations in Wistar rats for the augmented therapeutic effects against squamous cell carcinoma;International Journal of Biological Macromolecules;2023-12